WAVEMAN · COMPANY

ADTX · Aditxt, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

ADTX

Name: Aditxt, Inc. (ADTX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Aditxt, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001726711

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

$34.7K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-97.6%

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$34.7K over 180 days

+$176 over 90 days · +$34.7K of it by a 10%+ holder

more than 71% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

-97.6% year over year

below 93% of Pharma & Biotech

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

1.0 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Takeover Time 2026 LLC disclosed a 5%+ stake (10.9%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -100.0%

-100.0%12M

INSIDER BUYINSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows a net $34.7K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Aditxt, Inc. insiders bought a net $34.7K of stock across 27 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Takeover Time 2026 LLC

—

SELL

2026-06-23

3,420,439.0

$68.4K

HRT FINANCIAL LP

—

SELL

2026-06-22

5,120,480.0

$102.4K

HRT FINANCIAL LP

—

BUY

2026-06-18

7,340,178.0

$73.4K

DRW Securities, LLC

—

SELL

2026-06-17

126,772.0

$1.3K

HRT FINANCIAL LP

—

SELL

2026-06-16

3,132,480.0

$31.3K

27 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 22 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

IFP Advisors, Inc

1.0 sh

5%+ owners

13D = intent to influence · 13G = passive

Takeover Time 2026 LLC

ACTIVIST 13D · 2026-06-22

10.9%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$1.7K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$3.2K	$134.0K	$645.2K	$933.7K
GROSS PROFIT	$268	$-493.5K	$-111.7K	$166.9K
OPERATING INCOME	$-19.6M	$-27.9M	$-26.1M	$-25.5M
NET INCOME	$-43.1M	$-40.4M	$-32.7M	$-27.6M
EPS (DILUTED)	-1,153.83	-22,147,415.22	-27,038.26	-595.60
OPERATING CASH FLOW	$-25.7M	$-16.8M	$-19.2M	$-22.4M
CASH	—	$833.0K	$97.1K	$2.8M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE